GlycoMimetics Inc. (GLYC)
0.26
-0.01 (-4.34%)
At close: Mar 03, 2025, 3:59 PM
0.26
-0.34%
After-hours: Mar 03, 2025, 07:59 PM EST
No 1D chart data available
| Bid | 0.24 |
| Market Cap | 16.83M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -37.9M |
| EPS (ttm) | -0.59 |
| PE Ratio (ttm) | -0.44 |
| Forward PE | -2.8 |
| Analyst | n/a |
| Ask | 0.26 |
| Volume | 331,117 |
| Avg. Volume (20D) | 1,610,624 |
| Open | 0.26 |
| Previous Close | 0.27 |
| Day's Range | 0.26 - 0.27 |
| 52-Week Range | 0.14 - 3.18 |
| Beta | 1.81 |
About GLYC
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing G...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 10, 2014
Employees 4
Stock Exchange NASDAQ
Ticker Symbol GLYC
Website https://www.glycomimetics.com
4 months ago
+191.32%
GlycoMimetics shares are trading higher after the ...
Unlock content with
Pro Subscription
8 months ago
+25.28%
GlycoMimetics shares are trading higher after the company disclosed that Chief Medical Officer Edwin Rock bought 305,000 shares at an average price of $0.26 per share.
